2023-06-20 09:52:38 ET
Medical technology company, Nuwellis ( NUWE ) enters a supply and collaboration agreement with DaVita ( DVA ) to pilot Aquadex ultrafiltration therapy to treat adult patients with congestive heart failure and related conditions within select U.S. markets.
DaVita ( DVA ) provides extracorporeal therapies such as continuous renal replacement therapy and apheresis to patients across a network of hospitals and outpatient clinics.
The pilot program is expected to launch by the end of Q3 and extend through May 31, 2024.
In conjunction with the agreement, Nuwellis ( NUWE ) issued DaVita ( DVA ) a warrant for ~1.3M shares of Nuwellis stock. Nuwellis has also granted DaVita registration rights and rights to participate in future equity financings of Nuwellis.
For further details see:
Nuwellis along with DaVita will pilot therapy to treat patients with congestive heart failure